(Q40380082)

20 September 2017

title

Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases (English)

1 reference

20 September 2017

1 reference

Whang PG

1

1 reference

20 September 2017

Gamradt SC

series ordinal

2

1 reference

20 September 2017

Gates JJ

series ordinal

3

1 reference

20 September 2017

Lieberman JR

series ordinal

4

1 reference

20 September 2017

publication date

1 January 2005

1 reference

Prostate Cancer and Prostatic Diseases

20 September 2017

published in

1 reference

20 September 2017

volume

8

1 reference

20 September 2017

issue

4

1 reference

20 September 2017

page(s)

327-334

1 reference

20 September 2017

cites work

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Natural history of progression after PSA elevation following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Structure and functions of the 20S and 26S proteasomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Mechanisms underlying ubiquitination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

New insights into proteasome function: from archaebacteria to drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

How proteolysis drives the cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Roles of ubiquitin-mediated proteolysis in cell cycle control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

The ubiquitin-proteasome pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Increased and correlated nuclear factor-kappa B and Ku autoantigen activities are associated with development of multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

An essential role for NF-kappaB in preventing TNF-alpha-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Suppression of TNF-alpha-induced apoptosis by NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

The Measurement of Observer Agreement for Categorical Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

The proteasome is involved in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

7 January 2021

NF- kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF- kappa B

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

7 January 2021

Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

7 January 2021

The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

7 January 2021

Identifiers

DOI

10.1038/SJ.PCAN.4500823

1 reference

Dimensions Publication ID

20 September 2017

1006353609

0 references

1 reference